title: Therapy of recurrent squamous cell carcinoma of the head and neck using combination vincristine, bleomycin, and methotrexate. A Southwest Oncology Group Study.
abstract: Fifty-six patients with squamous cell carcinoma of the head and neck were treated with the combination of vincristine, bleomycin, and methotrexate (VBM) on an every 2-week schedule. The overall CR + PR rate was 20%. Median response duration was 10 weeks. The toxicity during this trial was comparable to previously reported VBM regimens. The response rate was less than or no better than those previously reported for VBM or methotrexate alone. Therefore, this regimen offers nothing over methotrexate alone or other VBM regimens.
mesh_terms: D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D008727:Methotrexate